News | EP Lab | May 16, 2018

Consumer Smart Watches Accurately Measure Paroxysmal Supraventricular Tachycardia

First-of-its-kind study includes results from Apple Watch, Samsung Galaxy Gear and Fitbit Charge 2

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT). #HRS2018

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT).  

May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced paroxysmal supraventricular tachycardia (PSVT), or episodes of rapid heart rate. Three common wearable devices including the Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2, were randomly assigned to patients to measure heart rate. The results were presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions. 

PSVT is marked by episodes of rapid heart rate (a heart rate above 100 beats per minute) that is caused by electrical impulses originating above the heart's ventricles. It affects approximately 2.5 per 1,000 adults and can impact people without any prior cardiovascular condition.[1] PSVT is often a cause of palpitations, which is one of the most common complaints of patients who seek medical care from an arrhythmia or cardiology clinic. Wearable devices are very popular and are now widely used not only to track fitness levels, but to also capture and monitor heart rates with photoplethysmography (PPG) technology. However, few studies are published that evaluate the accuracy of these devices especially in an arrhythmic situation. 

The study included 51 consecutive patients with a history of PSVT or paroxysmal palpitations who were schedule to undergo an electrophysiology study. The mean patient age was 44.4±16.6 years old and 53 percent were male. The study assessed three common wearable technologies, the Apple Watch Series 2 (Apple), Samsung Galaxy Gear S3 (Samsung) and the Fitbit Charge 2 (Fitbit). Patients were randomly assigned to wear two different devices, one on each wrist. The heart rate at baseline and during induced PSVT was evaluated. 

The baseline heart rate ranged from 50 to 101 beats per minute (bpm). The accuracy of the wearables at detecting baseline heart rate within five bpm was 100 percent, 100 percent and 94 percent for Apple, Samsung and Fitbit, respectively. Heart rate during PSVT ranged from 108 bpm to 228 bpm. The accuracy within 10 bpm was 100 percent, 100 percent and 88 percent for Apple, Samsung and Fitbit, respectively. The rate or type of PSVT, age and sex did not influence device accuracy. 

"Millions of people around the world are wearing smart watches or other devices that have the ability to track heart rate, and our study is the first of its kind to assess how effective and accurate these tools are for patients," said Jongmin Hwang, M.D., Seoul Asan Medical Center, Seoul, Korea. "As clinicians, we see these devices as a tool to help patients learn more about their heart health and become more proactive about self-care. With technology delivering information literally to their fingertips, we hope patients will be better informed and more inclined to speak with their doctor about their health." 

To further validate the results of this study, the authors attempted measurement during rapid atrial and ventricular pacing after successful ablation to stimulate tachycardia. Initial findings again show an acceptable accuracy, however there were performance differences between devices. The Apple Watch showed highest accuracy and Galaxy was comparable. 

Heart Rhythm 2018 is the most comprehensive educational program for heart rhythm professionals, featuring more than 200 educational sessions and more than 140 exhibitors showcasing innovative products and services. For more information: www.hrssessions.org

Related Content on Consumer-grade wearables To Detect Arrhythmias:

Artificial Intelligence Detects AFib Using Apple Watch Heart Rate Sensor

Movement Toward Simpler, Wearable Cardiac Monitoring

Clinical Study Uses Consumer Wearables to Anticipate Illness

 

Find links to all the Heart Rhythm 2018 Late-breaking Studies

Reference:

1. Ferguson, JD, DiMarco, JP. Contemporary Management of Paroxysmal Supraventricular Tachycardia. Circulation. 2003; 107: 1096-1099. Doi: 10.1161/01/CIR.0000059743.36226.E8
 

#HRS2018  #HRS18

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init